Marker Therapeutics (MRKR) has released an update.
Marker Therapeutics has announced significant strides in its immuno-oncology programs, including promising preliminary results from its lymphoma treatment study and strategic funding gains. The biotech firm secured a $2 million grant from the NIH to support its Acute Myeloid Leukemia treatment program and received an Orphan Drug Designation in Europe, while also making key leadership appointments and extending its financial runway into late 2025.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
